Class A61P : THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
Subclass 3/10: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P 7/00) for glucose homeostasis (pancreatic hormones A61P 5/48) for hyperglycaemia, e.g. antidiabetics
| Patent # | Title | Filing Date | Issue Date | Patent Owner |
|---|---|---|---|---|
| 11998542 | Compositions and methods for reducing major adverse cardiovascular events | Nov 16, 20 | Jun 04, 24 | Nalpropion Pharmaceuticals LLC |
| 11999677 | Benzylamino-oxoethyl benzamide analogs and methods of use | Feb 08, 22 | Jun 04, 24 | The Board of Regents of the University of Oklahoma |
| 11999722 | Disubstituted pyrazole compounds | Sep 17, 21 | Jun 04, 24 | Applied Molecular Evolution Inc. c/o Eli Lilly and Company Patent Division |
| 11999740 | Fused pyrazine derivatives as A2A / A2B inhibitors | Oct 13, 21 | Jun 04, 24 | Incyte Corporation |
| 11992477 | Pharmaceutical combination, composition, and combination preparation comprising glucokinase activator and SGLT-2 inhibitor and preparation methods and uses thereof | May 28, 19 | May 28, 24 | Hua Medicine (Shanghai) Ltd. |
| 11992487 | Quinolines that modulate SERCA and their use for treating disease | Aug 02, 23 | May 28, 24 | Neurodon Corporation |
| 11992506 | Stem cell derived pancreatic islet differentiation | Nov 01, 22 | May 28, 24 | Vertex Pharmaceuticals Incorporated |
| 11987619 | Single-chain chimeric polypeptides and uses thereof | Jul 21, 22 | May 21, 24 | HCW Biologics, Inc. |
| 11980614 | Methods of treating RBP4 related diseases with triazolopyridines | Apr 12, 21 | May 14, 24 | Belite Bio, Inc; The Trustees of Columbia University in the City of New York; |
| 11981928 | Methods for reducing elevated glucose levels | Sep 28, 18 | May 14, 24 | SDF BIOPHARMA INC. |
| 11974989 | Therapeutic uses of glucokinase activators in combination with insulin or insulin analogs | Feb 18, 21 | May 07, 24 | vTv Therapeutics LLC |
| 11974990 | TXNIP-TRX complex inhibitors and methods of using the same | Apr 06, 22 | May 07, 24 | City of Hope |
| 11976083 | Inhibitors of peptidylarginine deiminases | Apr 28, 21 | May 07, 24 | Gilead Sciences, Inc. |
| 11976282 | GATA3 inhibitors for the promotion of subcutaneous fat deposition | Jun 23, 20 | May 07, 24 | QATAR UNIVERSITY |
| 11969435 | Concomitant administration of glucocorticoid receptor modulators and CYP3A inhibitors | Dec 07, 21 | Apr 30, 24 | Corcept Therapeutics, Inc. |
| 11970523 | Long-acting oxyntomodulin hybrid peptide, preparation method therefor, and application thereof | May 06, 19 | Apr 30, 24 | China Pharmaceutical University |
| 11963947 | Pharmaceutical combination, composition and compound preparation comprising glucokinase activator and DPP-IV inhibitor, and preparation method and use thereof | May 28, 19 | Apr 23, 24 | Hua Medicine (Shanghai) Ltd. |
| 11963989 | Application of medical cell CMU-pb-7 in preparation of blood lipid-lowering drugs | Jun 17, 23 | Apr 23, 24 | GUANGDONG XINGHAI BIOTECHNOLOGY CO., LTD.; GUANGDONG XINGHAI INSTITUTE OF CELL; |
| 11964938 | 3-phenyl-4-hexynoic acid derivatives as GPR40 agonists | Jan 07, 19 | Apr 23, 24 | CELON PHARMA S.A. |
| 11964984 | TXNIP-TRX complex inhibitors and methods of using the same | Apr 15, 21 | Apr 23, 24 | Beckman Research Institute City of Hope |
| Publication # | Title | Filing Date | Pub Date | Patent Owner |
|---|---|---|---|---|
| 2024/0180,870 | METHODS OF TREATING CONDITIONS RELATED TO THE S1P1 RECEPTOR | Jan 08, 24 | Jun 06, 24 | Arena Pharmaceuticals, Inc. |
| 2024/0180,891 | SYNERGISTIC MODULATORS OF ALPHA-DICARBONYL DETOXIFICATION AND THEIR USE FOR INDUCING WEIGHT LOSS AND THE TREATMENT OF DIABETIC PATHOLOGIES | Dec 20, 21 | Jun 06, 24 | BUCK INSTITUTE FOR RESEARCH ON AGING |
| 2024/0180,941 | ACTIVE AGENTS AND METHODS OF THEIR USE FOR THE TREATMENT OF METABOLIC DISORDERS AND NONALCOHOLIC FATTY LIVER DISEASE | Oct 26, 23 | Jun 06, 24 | Not available |
| 2024/0180,942 | NUTRITIONAL SUPPLEMENT AND USES | Apr 19, 22 | Jun 06, 24 | CITROX BIOSCIENCES LIMITED |
| 2024/0180,977 | COMPOSITIONS AND METHODS RELATING TO CLOSTRIDIUM COCHLEARIUM AND LACTOBACILLUS ACIDOPHILUS | Jun 06, 23 | Jun 06, 24 | Not available |
| 2024/0181,013 | POEGMA COPOLYMER CONJUGATES AND METHODS OF TREATING DISEASES | Apr 01, 22 | Jun 06, 24 | Not available |
| 2024/0181,015 | EFFECT OF GHRH ANTAGONISTS IN DIABETES AND OBESITY | Apr 04, 22 | Jun 06, 24 | Augusta University Research Institute, Inc.; Biomm Inc. & University of Miami; THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPT. OF VETERANS AFFAIRS; |
| 2024/0181,016 | POLYPEPTIDE CONJUGATES AND METHODS OF USES | Nov 03, 22 | Jun 06, 24 | Not available |
| 2024/0182,925 | INSULIN GENE THERAPY TO TREAT DIABETES | Mar 16, 22 | Jun 06, 24 | Not available |
| 2024/0173,262 | MUCOADHESIVE PHARMACEUTICAL DOSAGE FORM FOR UNIDIRECTIONAL RELEASE OF PEPTIDE THERAPEUTIC PARTICLES | Nov 17, 23 | May 30, 24 | The University of British Columbia |
| 2024/0173,305 | RAPAMYCIN ANALOGS AND USES THEREOF | Dec 04, 23 | May 30, 24 | Not available |
| 2024/0173,381 | HB-EGF GENE THERAPY FOR DIABETES | Mar 02, 22 | May 30, 24 | Kagoshima University |
| 2024/0173,428 | METHODS AND COMPOUNDS FOR TARGETED AUTOPHAGY | Apr 18, 23 | May 30, 24 | Not available |
| 2024/0174,646 | METHYLLACTAM RING COMPOUND AND PHARMACEUTICAL USE THEREOF | Jun 28, 23 | May 30, 24 | Not available |
| 2024/0174,733 | ACTRII PROTEINS AND USES THEREOF | Mar 09, 22 | May 30, 24 | Not available |
| 2024/0174,983 | METHOD OF INCREASING PROLIFERATION OF PANCREATIC BETA CELLS, TREATMENT METHOD, AND COMPOSITION | Jul 18, 23 | May 30, 24 | Not available |
| 2024/0165,114 | TREATMENT OF DIABETIC NEPHROPATHY WITH AN sGC STIMULATOR | Oct 28, 20 | May 23, 24 | Not available |
| 2024/0166,601 | NLRX1 LIGANDS | Jun 19, 23 | May 23, 24 | LANDOS BIOPHARMA, INC. |
| 2024/0156,767 | SCREENING METHOD FOR GLP-1 SECRETION REGULATION AGENT, GLP-1 SECRETION REGULATION AGENT, COMPOSITION FOR PREVENTING OR AMELIORATING DIABETES, OBESITY, POSTPRANDIAL HYPERGLYCEMIA, NEURODEGENERATIVE DISEASE, HYPOGLYCEMIA, ADIPOSITY, OR NESIDIOBLASTOSIS, METHOD FOR PROMOTING SECRETION OF GLP-1 IN GPR84-EXPRESSING CELLS, METHOD FOR PRODUCING COMPOSITION FOR PROMOTING SECRETION OF GLP-1, USE OF GPR84 AGONIST FOR PRODUCING THERAPEUTIC AGENT FOR DISEASE, GLP-1 SECRETION PROMOTION AGENT, AND... | Jan 25, 22 | May 16, 24 | Not available |
| 2024/0156,987 | NUCLEIC ACID PRODUCTS AND METHODS OF ADMINISTRATION THEREOF | Jun 02, 23 | May 16, 24 | Not available |
| Upgrade to the Professional Level to view Top Owners for this Subclass.Learn More |
|---|
